Importance Heart failure with preserved ejection fraction (HFpEF), defined as HF with an EF
of 50% or higher at diagnosis, affects approximately 3 million people in the US and up to 32 …

The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF)
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …

Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise
function and reduced body weight in patients with obesity phenotype of heart failure and …

Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality in
individuals with type 2 diabetes mellitus (T2DM). Secular changes in CVD outcomes have …

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …

Background The majority of patients with heart failure with preserved ejection fraction
(HFpEF) have the obesity phenotype, but no therapies specifically targeting obesity in …

BACKGROUND: Patients with heart failure (HF) with preserved ejection fraction (HFpEF)
and obesity experience a high burden of symptoms and functional impairment, and a poor …